Quarterly ResultMay 14, 2026, 04:23 PM
Larimar Therapeutics Q1 Net Loss $29.6M; Cash $200.4M
AI Summary
Larimar Therapeutics reported a net loss of $29.6 million for the first quarter of 2026, a slight increase from $29.3 million in the prior year. The company significantly bolstered its liquidity, ending the quarter with $200.4 million in cash, cash equivalents, and marketable securities, up from $136.8 million at the end of 2025, primarily due to a $107.6 million equity offering in February 2026. The company anticipates its current capital will fund operations for at least the next twelve months.
Key Highlights
- Net loss for Q1 2026 was $29.6 million, compared to $29.3 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $200.4 million as of March 31, 2026.
- This represents an increase from $136.8 million as of December 31, 2025.
- Proceeds from equity issuance in Q1 2026 were $108.1 million.
- Research and development expenses decreased to $25.0 million in Q1 2026 from $26.6 million in Q1 2025.
- General and administrative expenses increased to $6.1 million in Q1 2026 from $4.6 million in Q1 2025.
- Net cash used in operating activities was $44.6 million for Q1 2026.
- Company expects current capital to fund operations for at least 12 months.